Clinical trials located in

Mont-de-Marsan

Mont-de-Marsan city is located in France. Currently, 5 clinical trials are being conducted in this city.

Mont-de-Marsan, the capital of the Landes department in southwestern France, is nestled at the confluence of the Douze and Midou rivers. Founded in 1133, this city is renowned for its rich military history and vibrant cultural scene. Mont-de-Marsan is home to the Despiau-Wlérick Museum, dedicated to figurative sculpture, showcasing over 800 works. The city also hosts the Fêtes de la Madeleine, a lively five-day festival every July, celebrating local traditions and bullfighting events, reflecting its unique blend of Gascon and Basque cultures.

  • CT-EU-00057161

    Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Study on belantamab mafodotin use for multiple myeloma retreatments

    This study is about a treatment called belantamab mafodotin for people with a disease called multiple myeloma that has come back and is not responding well to treatment. Belantamab mafodotin is a drug that attaches to an antigen, a marker found on cancer cells, and then destroys the cancer cells. In this study, patients will be randomly assigned to receive belantamab mafodotin on its own or in combination with other cancer treatments. The researchers will monitor patients’ blood and urine to see how the treatment is working and to check for any side-effects. If patients respond well to the treatment, they may have a reduction in the size of their cancer.

    • Belantamab mafodotin
    • GSK3174998- new potential medication for solid tumors
    • Nirogacestat
    • Pomalidomide
    • Feladilimab
    • Dostarlimab
    • Isatuximab
    • Lenalidomide
    • Dexamethasone
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in France:

.